Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Pliant Therapeutics, Inc. (Nasdaq: PLRX) has announced the granting of stock options to Gary Palmer, M.D., the company's newly appointed Senior Vice President of Medical Affairs. The grant, made on September 30, 2024, includes options to purchase 120,000 shares of common stock as a material inducement to his employment.
The stock options have an exercise price of $11.21 per share, equal to the closing price of Pliant's common stock on the grant date. The options will vest over 4 years, with 25% vesting on the one-year anniversary and the remaining shares vesting monthly at a rate of 1/48th over the subsequent 36 months. The stock options have a 10-year term and are subject to the terms and conditions of the Company's 2022 Inducement Plan.
Pliant Therapeutics, Inc. (Nasdaq: PLRX) ha annunciato il conferimento di opzioni su azioni a Gary Palmer, M.D., il nuovo eletto Vice Presidente della Divisione Medica dell'azienda. Il conferimento, effettuato il 30 settembre 2024, include opzioni per l'acquisto di 120.000 azioni ordinarie come incentivo materiale per la sua assunzione.
Le opzioni azionarie hanno un prezzo di esercizio di $11.21 per azione, equivalente al prezzo di chiusura delle azioni ordinarie di Pliant nella data del conferimento. Le opzioni matureranno in un periodo di 4 anni, con il 25% che matura al primo anniversario e le azioni rimanenti che maturano mensilmente a un tasso di 1/48 nei successivi 36 mesi. Le opzioni azionarie hanno un termine di 10 anni e sono soggette ai termini e alle condizioni del Piano di Incentivi del 2022 dell'azienda.
Pliant Therapeutics, Inc. (Nasdaq: PLRX) ha anunciado la concesión de opciones sobre acciones a Gary Palmer, M.D., el recientemente nombrado Vicepresidente Senior de Asuntos Médicos de la compañía. La concesión, realizada el 30 de septiembre de 2024, incluye opciones para comprar 120,000 acciones ordinarias como incentivo material para su empleo.
Las opciones sobre acciones tienen un precio de ejercicio de $11.21 por acción, que corresponde al precio de cierre de las acciones ordinarias de Pliant en la fecha de concesión. Las opciones se consolidarán durante 4 años, con el 25% consolidándose en el primer aniversario y las acciones restantes consolidándose mensualmente a un ritmo de 1/48 en los siguientes 36 meses. Las opciones sobre acciones tienen un plazo de 10 años y están sujetas a los términos y condiciones del Plan de Inducción 2022 de la compañía.
Pliant Therapeutics, Inc. (Nasdaq: PLRX)는 회사의 새로 임명된 의학 담당 수석 부사장인 Gary Palmer, M.D.에게 주식 옵션을 부여했다고 발표했습니다. 이 부여는 2024년 9월 30일에 이루어졌으며, 그의 고용을 위한 실질적인 유인으로 120,000주의 보통주를 구매할 수 있는 옵션을 포함합니다.
주식 옵션의 행사 가격은 주당 $11.21로, 부여 당일 Pliant의 보통주 종가와 같습니다. 옵션은 4년에 걸쳐 만료되며, 1년 기념일에 25%가 만료되고 나머지 주식은 이후 36개월 동안 매달 1/48 비율로 만료됩니다. 주식 옵션의 유효 기간은 10년이며, 회사의 2022 유도 계획의 조건에 따릅니다.
Pliant Therapeutics, Inc. (Nasdaq: PLRX) a annoncé l'octroi d'options sur actions à Gary Palmer, M.D., le nouveau Vice-Président senior des affaires médicales de l'entreprise. L'octroi, effectué le 30 septembre 2024, comprend des options pour acheter 120 000 actions ordinaires en tant qu'incitation matérielle à son emploi.
Les options sur actions ont un prix d'exercice de 11,21 $ par action, correspondant au prix de clôture des actions ordinaires de Pliant à la date de l'octroi. Les options seront acquises sur une période de 4 ans, avec 25 % acquises à l'anniversaire d'un an et le reste des actions acquises mensuellement à un rythme de 1/48 au cours des 36 mois suivants. Les options sur actions ont une durée de 10 ans et sont soumises aux termes et conditions du Plan d'incitation 2022 de la société.
Pliant Therapeutics, Inc. (Nasdaq: PLRX) hat die Gewährung von Aktienoptionen an Gary Palmer, M.D., den neu ernannten Senior Vice President für Medizinische Angelegenheiten des Unternehmens, bekannt gegeben. Die Gewährung, die am 30. September 2024 erfolgte, umfasst Optionen zum Kauf von 120.000 Aktien als wesentliche Anreize für seine Anstellung.
Die Aktienoptionen haben einen Ausübungspreis von $11.21 pro Aktie, was dem Schlusskurs der ordentlichen Aktien von Pliant an dem Tag der Gewährung entspricht. Die Optionen verfallen über einen Zeitraum von 4 Jahren, wobei 25% am ersten Jahrestag verfallen und die verbleibenden Aktien monatlich mit einer Rate von 1/48 über die folgenden 36 Monate verfallen. Die Aktienoptionen haben eine Laufzeit von 10 Jahren und unterliegen den Bedingungen des Unternehmensplans zur Anreizgestaltung von 2022.
- Appointment of Gary Palmer, M.D. as Senior Vice President of Medical Affairs
- Granting of stock options as an incentive for key executive talent
- Potential dilution of existing shareholders due to the issuance of 120,000 new stock options
SOUTH SAN FRANCISCO, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced that on September 30, 2024 it granted stock options to purchase an aggregate of 120,000 shares of common stock upon vesting to Gary Palmer, M.D., the Company’s newly appointed Senior Vice President of Medical Affairs as a material inducement to his employment.
The stock options that were granted are subject to an exercise price of
About Pliant Therapeutics, Inc.
Pliant Therapeutics is a late-stage biopharmaceutical company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases. Pliant's lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. Bexotegrast has received Fast Track Designation and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in IPF and PSC and Orphan Drug Designation from the European Medicines Agency in IPF and PSC. Pliant has initiated BEACON-IPF, an adaptive Phase 2b/3 trial of bexotegrast in IPF. Pliant is conducting a Phase 1 study for its third clinical program, PLN-101095, a small molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, that is being developed for the treatment of solid tumors. In addition, Pliant has received regulatory clearance for the conduct of a Phase 1 study of PLN-101325, a monoclonal antibody agonist of integrin α7β1 targeting muscular dystrophies.
For additional information, please visit: www.PliantRx.com. Follow us on social media: X, LinkedIn, and Facebook.
Investor and Media Contact:
Christopher Keenan
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
ir@pliantrx.com
FAQ
How many stock options did Pliant Therapeutics (PLRX) grant to Gary Palmer?
What is the exercise price of the stock options granted by Pliant Therapeutics (PLRX) on September 30, 2024?
What is the vesting schedule for the stock options granted by Pliant Therapeutics (PLRX)?
What position was Gary Palmer appointed to at Pliant Therapeutics (PLRX)?
